Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinsuke Iida

Showing results (141-150 of 290) with videos related to

Pageof 29
Sort By:
Frontiers in Oncology|March 27, 2025
Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature reviewFrancesca Gay, Elena Zamagni, Craig Emmitt Cole, et al.
International Journal of Hematology|August 19, 2021
Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trialKenshi Suzuki, Chang-Ki Min, Kihyun Kim, et al.
Blood Cancer Journal|December 4, 2025
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myelomaMeletios A Dimopoulos, Sagar Lonial, Wee-Joo Chng, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|May 15, 2020
Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapyTakaki Kikuchi, Shigeru Kusumoto, Yasuhito Tanaka, et al.
Journal of Cancer Research and Clinical Oncology|June 3, 2021
Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of MyelomaShuji Ozaki, Hiroshi Handa, Hiromi Koiso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphomaTakashi Ishida, Shinsuke Iida, Yoshiki Akatsuka, et al.
Acta Haematologica|January 18, 2018
Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in JapanTsuyoshi Muta, Toshihiro Miyamoto, Tomohiko Kamimura, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 9, 2018
[Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance mimicking POEMS syndrome]Takashi Kanamori, Shigeru Kusumoto, Kenji Okita, et al.
Scientific Reports|May 5, 2021
Periplocin and cardiac glycosides suppress the unfolded protein responseMuneshige Tokugawa, Yasumichi Inoue, Kan'ichiro Ishiuchi, et al.
Journal for Immunotherapy of Cancer|July 14, 2025
JAK-STAT-activated, fratricide-resistant CAR-T cells targeting membrane-bound TNF effectively treat AML and solid tumorsTakahiro Nakashima, Tsunenori Ouchida, Yuichi Ishikawa, et al.
Pageof 29

Showing results (141-150 of 290) with videos related to

Sort By:
Pageof 29
Frontiers in Oncology|March 27, 2025
Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature reviewFrancesca Gay, Elena Zamagni, Craig Emmitt Cole, et al.
International Journal of Hematology|August 19, 2021
Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trialKenshi Suzuki, Chang-Ki Min, Kihyun Kim, et al.
Blood Cancer Journal|December 4, 2025
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myelomaMeletios A Dimopoulos, Sagar Lonial, Wee-Joo Chng, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|May 15, 2020
Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapyTakaki Kikuchi, Shigeru Kusumoto, Yasuhito Tanaka, et al.
Journal of Cancer Research and Clinical Oncology|June 3, 2021
Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of MyelomaShuji Ozaki, Hiroshi Handa, Hiromi Koiso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphomaTakashi Ishida, Shinsuke Iida, Yoshiki Akatsuka, et al.
Acta Haematologica|January 18, 2018
Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in JapanTsuyoshi Muta, Toshihiro Miyamoto, Tomohiko Kamimura, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 9, 2018
[Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance mimicking POEMS syndrome]Takashi Kanamori, Shigeru Kusumoto, Kenji Okita, et al.
Scientific Reports|May 5, 2021
Periplocin and cardiac glycosides suppress the unfolded protein responseMuneshige Tokugawa, Yasumichi Inoue, Kan'ichiro Ishiuchi, et al.
Journal for Immunotherapy of Cancer|July 14, 2025
JAK-STAT-activated, fratricide-resistant CAR-T cells targeting membrane-bound TNF effectively treat AML and solid tumorsTakahiro Nakashima, Tsunenori Ouchida, Yuichi Ishikawa, et al.
Pageof 29